





epkinly[™]
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg | 48mg

A Conversation Guide for New Patients



Actor portrayal.

This tool is designed to help you communicate with your healthcare team as you begin treatment with EPKINLY. It includes questions you may wish to ask your healthcare provider, as well as space to take notes during your appointments.

What is EPKINLY?

EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma that has come back or that did not respond to previous treatment after receiving 2 or more treatments. EPKINLY is approved based on patient response data. A study is ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children.

SELECT IMPORTANT SAFETY INFORMATION

EPKINLY can cause serious side effects including cytokine release syndrome (CRS), neurologic problems, infections, and low blood cell counts.

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 4-5. Please see [Medication Guide](https://www.epkinly.com/medguide) at [EPKINLYMedGuide.com](https://www.epkinly.com/medguide).



Questions about EPKINLY

Questions to ask your healthcare provider during treatment

Check off the boxes of questions you would like to ask your healthcare provider to help guide your discussion. Use the space here and on the next page to take notes during your appointments.

Is there anything else I need to be aware of while I am receiving EPKINLY?

Where will I be given my first full dose of EPKINLY?

Is there anything more I can do to make my overall health better during treatment?

What tests will I need during treatment?

Are there other resources that can help me manage possible side effects during treatment?

When and how will I know if the treatment is working?

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 4-5. Please see Medication Guide at EPKINLYMedGuide.com.


epcoritamab-bysp[™]
SUBCUTANEOUS INJECTION 4mg|48mg

Important Safety Information

What is EPKINLY?

EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma that has come back or that did not respond to previous treatment after receiving 2 or more treatments. EPKINLY is approved based on patient response data. A study is ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Important Warnings—EPKINLY can cause serious side effects, including:

- **Cytokine release syndrome (CRS)**, which is common during treatment with EPKINLY and can be serious or life-threatening. To help reduce your risk of CRS, you may receive other medicines before receiving EPKINLY and you will also be given smaller doses of EPKINLY for the first 2 doses (called “step-up” dosing). Your first full dose of EPKINLY will be given on day 15 of your first cycle of treatment and you should be hospitalized for 24 hours after due to risk of CRS and neurologic problems. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule.
- **Neurologic problems** that can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY.

Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing;

chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. **These may be symptoms of CRS or neurologic problems. Do not** drive or use heavy machinery or do other dangerous activities if you have any symptoms that impair consciousness until your symptoms go away.

EPKINLY can cause other serious side effects, including:

- **Infections** that may lead to death. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, or feeling weak or generally unwell.
- **Low blood cell counts** are common during treatment with EPKINLY and can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems.

Please see additional Important Safety Information on page 5.
Please see [Medication Guide at EPKINLYMedGuide.com](#).


epkinly™
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg

Important Safety Information (continued)

Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. **If you are a female who can become pregnant,** your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.

The most common side effects of EPKINLY include CRS, tiredness, muscle and bone pain, injection site reactions, fever, stomach-area (abdominal) pain, nausea, and diarrhea. These are not all the possible side effects of EPKINLY. Call your doctor for medical advice about side effects.

You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622).

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on page 4. Please see [Medication Guide at EPKINLYMedGuide.com](#).



Distributed and marketed by Genmab US, Inc. 777 Scudders Mill Road, Plainsboro, NJ 08536.
Distributed and marketed by AbbVie Inc. 1 North Waukegan Road, North Chicago, IL 60064.
EPKINLY is a trademark of Genmab A/S.
©2023 Genmab A/S and AbbVie. All rights reserved.
12/2023 COM-US-EPK-0000250

